Posted by Michael Wonder on 04 Aug 2020
Janssen announces Health Canada approval of Darzalex SC, a new subcutaneous formulation for the treatment of patients with multiple myeloma
4 August 2020 - Darzalex SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous Darzalex (daratumumab).
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has approved Darzalex SC (daratumumab), a new subcutaneous formulation of daratumumab.
Darzalex SC is approved in four regimens across five indications in patients with multiple myeloma, most notably newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.
